Document:

EXHIBIT
4.12 

 

Amendment
No. 3 to 

UNSECURED
Convertible PROMISSORY Note

 

THIS
AMENDMENT NO. 3 TO UNSECURED CONVERTIBLE PROMISSORY NOTE (this “Amendment”) is made and entered into as
of July [*], 2022, by and between bioAffinity Technologies, Inc. a Delaware corporation (“Company”), and [Name
of Payee] (“Payee”).

 

RECITALS

 

WHEREAS,
pursuant to that certain Unsecured Convertible Promissory Note dated [Date of Original Note], payable by Company to Payee in the
original principal amount of $[Principal Amount of Original Note], as amended by that certain Amendment No. 1 to Unsecured Convertible
Promissory Note made and entered into effective as of October 31, 2021, and that certain Amendment No. 2 to Unsecured Convertible Promissory
Note made and entered into effective as of May 31, 2022 (the “Note”), the accrued but unpaid interest on, and
outstanding principal of, the Note are due and payable in full on or before August 31, 2022; and

 

WHEREAS,
the Company and Payee desire to extend the maturity date of the accrued but unpaid interest and outstanding principal of the Note to
October 31, 2022.

 

NOW,
THEREFORE, Company and Payee hereby agree as follows:

 

AGREEMENT

 

Company
and Payee agree that, effective as of the date hereof, the Note is hereby amended such that the “Maturity Date” as defined
in the first paragraph of the Note is extended from August 31, 2022, to October 31, 2022.

 

This
Amendment is being entered into in reliance on, in consideration for, and contingent upon the Company issuing to Payee a common stock
purchase warrant (a “Warrant”) enabling Payee to purchase that number of shares of Company common stock equal to the
quotient obtained by dividing the principal amount of the Note by 10.5 at a purchase price equal to $5.25 per share.

 

Except
as expressly modified hereby, the Note (as amended) shall remain in full force and effect and is hereby ratified and confirmed by the
parties hereto. Company further acknowledges (a) that the Note is fully enforceable against Company, in accordance with the terms of
the Note, and (b) that Company has no right of set-off, counterclaim, or defense to the indebtedness evidenced by the Note, as modified
hereby. This Amendment shall not constitute a novation of the Note or the indebtedness evidenced thereby.

 

This
Amendment may be executed in multiple counterparts, each of which shall constitute an original and all of which taken together shall
constitute one and the same instrument. This Amendment may be executed by facsimile, telecopy or other electronic means, and such execution
shall be considered valid, binding and effective for all purposes.

 

This
Amendment shall bind and inure to the benefit of the parties hereto and their respective heirs, executors, legal representatives, successors,
and assigns.

 

    	1

    	 

    

 

IN
WITNESS WHEREOF, the duly authorized representatives of the undersigned have each executed this Amendment, effective as of the date
first above written.

 

	 	COMPANY:
	 	 
	 	bioAffinity
    Technologies, Inc.
	 	a
    Delaware corporation
	 	 	 
	 	By:
    	 
	 	 	Maria
    Zannes
	 	 	Chief
    Executive Officer

 

	 	PAYEE:
	 	 
	 	[Payee
    on Original Note]
	 	 	      
	 	By:
    	 
	 	Name:	 
	 	Title:	

 

    	2EXHIBIT
4.13 

 

Amendment
No. 2 to 

Convertible
PROMISSORY Note

 

THIS
AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE (this “Amendment”) is made and entered into as of July [*],
2022, by and between bioAffinity Technologies, Inc. a Delaware corporation (“Company”), and [Name of Payee]
(“Payee”).

 

RECITALS

 

WHEREAS,
pursuant to that certain Convertible Promissory Note dated [Date of Original Note], payable by Company to Payee in the original principal
amount of $[Principal Amount of Original Note], as amended by that certain Amendment No. 1 to Convertible Promissory Note made and entered
into effective as of May 31, 2022 (the “Note”), the accrued but unpaid interest on, and outstanding principal
of, the Note are due and payable in full on or before August 31, 2022; and

 

WHEREAS,
the Company and Payee desire to extend the maturity date of the accrued but unpaid interest and outstanding principal of the Note to
October 31, 2022.

 

NOW,
THEREFORE, Company and Payee hereby agree as follows:

 

AGREEMENT

 

Company
and Payee agree that, effective as of the date hereof, the Note is hereby amended such that the “Maturity Date” as defined
in the first paragraph of the Note is extended from August 31, 2022, to October 31, 2022.

 

This
Amendment is being entered into in reliance on, in consideration for, and contingent upon the Company issuing to Payee a common stock
purchase warrant (a “Warrant”) enabling Payee to purchase that number of shares of Company common stock equal to the
quotient obtained by dividing the principal amount of the Note by 10.5 at a purchase price equal to $5.25 per share.

 

Except
as expressly modified hereby, the Note (as amended) shall remain in full force and effect and is hereby ratified and confirmed by the
parties hereto. Company further acknowledges (a) that the Note is fully enforceable against Company, in accordance with the terms of
the Note, and (b) that Company has no right of set-off, counterclaim, or defense to the indebtedness evidenced by the Note, as modified
hereby. This Amendment shall not constitute a novation of the Note or the indebtedness evidenced thereby.

 

This
Amendment may be executed in multiple counterparts, each of which shall constitute an original and all of which taken together shall
constitute one and the same instrument. This Amendment may be executed by facsimile, telecopy or other electronic means, and such execution
shall be considered valid, binding and effective for all purposes.

 

This
Amendment shall bind and inure to the benefit of the parties hereto and their respective heirs, executors, legal representatives, successors,
and assigns.

 

    	1

    	 

    

 

IN
WITNESS WHEREOF, the duly authorized representatives of the undersigned have each executed this Amendment, effective as of the date
first above written.

 

	 	COMPANY:
	 	 
	 	bioAffinity
    Technologies, Inc.
	 	 a
    Delaware corporation
	 	 	 
	 	By:
    	
	 	 	Maria
    Zannes
	 	 	Chief
    Executive Officer

 

	 	PAYEE:
	 	 
	 	[Payee
    on Original Note]
	 	 	          
	 	By:
    	
	 	Name:	
	 	Title:	

 

    	2Exhibit
4.14 

 

THE
SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE
STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT
AND QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS, OR UNLESS THE CORPORATION HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE,
REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION OR QUALIFICATION IS NOT REQUIRED.

 

bioaffinity
technologies, Inc.

 

Warrant

  

THIS
WARRANT (this “Warrant”) is dated as of ______________, 2022 (the “Effective Date”) and entered
into by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and [____________________]
(the “Holder”).

 

A.
To induce the Holder to enter into that certain [Amendment to Convertible Promissory Note] (the “Amendment”) dated
as of _________________, 2022, by and between the Company and the Holder, the Company has agreed to issue this Warrant to the Holder.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree
as follows:

 

1.
Certain Definitions.

 

(a)
“Common Stock” means the Company’s Common Stock, par value $0.007 per share.

 

(b)
“Expiration Date” shall be the date that is the fifth (5th) anniversary of the Effective Date.

 

(c)
“Holder” has the meaning given in the recitals of this Warrant.

 

2.
Exercise of Warrant.

 

(a)
Holder is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or prior to the Expiration Date,
but not thereafter, to purchase from the Company up to [________] shares of Common Stock at an exercise price of $5.25 per share (the
“Per Share Exercise Price”).

 

    	 

    	 

    

 

(b)
The purchase rights represented by this Warrant are exercisable by the Holder, in whole or in part, at any time before the close of business
on the Expiration Date, by the surrender of this Warrant (or the applicable portion thereof) and the delivery to the Company of a duly
executed Notice of Exercise in the form annexed hereto, at the Company’s principal executive office (or such other office or agency
of the Company as it may designate by notice in writing to the Holder at the address of the Holder appearing on the books of the Company),
and upon payment of the aggregate Per Share Exercise Price for the shares of Common Stock thereby purchased (by cash or by check or bank
draft payable to the order of the Company), whereupon the Holder shall be entitled to receive a certificate for the number of shares
of Common Stock so purchased. If, prior to the Expiration Date, the Holder exercises this Warrant for less than all of the shares of
Common Stock that would be issuable upon the exercise of this Warrant in full, then the Company, upon receipt of this Warrant for cancellation,
shall issue a new Warrant to the Holder representing the balance of such shares of Common Stock. The Company agrees that if at the time
of the surrender of this Warrant and purchase of the shares of Common Stock, the Holder shall be entitled to exercise this Warrant, the
shares of Common Stock so purchased shall be and be deemed to be issued to the Holder as the record owner of such shares of Common Stock
as of the close of business on the date on which this Warrant shall have been exercised as aforesaid.

 

(c)
The Company shall at all times during the period for which this Warrant is exercisable, reserve and keep available such number of shares
of Common Stock as will be sufficient to effect the exercise of this Warrant in full; and if at any such time the number of authorized
but unissued shares of Common Stock shall not be sufficient to effect the exercise of this Warrant in full, the Company will take such
corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to
such number of securities as shall be sufficient for such purpose including, without limitation, engaging its best efforts to obtain
the requisite security holder approval for any necessary amendment to the Company charter documents and shall pay all fees and expenses
necessarily incurred by the Company in connection therewith.

 

3.
Nonassessable. The Company covenants that all shares of Common Stock which may be issued upon the exercise of rights represented
by this Warrant will, upon exercise of the rights represented by this Warrant, be validly issued, fully paid and nonassessable and free
from all taxes, liens and charges in respect of the issue thereof. Certificates for shares of Common Stock purchased hereunder shall
be delivered to the Holder as soon as reasonably practicable after the date on which this Warrant shall have been exercised.

 

4.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. Any fraction of a share that would otherwise be issuable upon the exercise of this Warrant shall be rounded down to
the nearest whole share.

 

5.
Charges, Taxes and Expenses. Issuance of certificates for shares of Common Stock upon the exercise of this Warrant shall be made
without charge to the Holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate,
all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder.

 

6.
No Rights as Shareholder. This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder of the
Company prior to the exercise hereof.

 

7.
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall be a Saturday, a Sunday or a legal holiday, then such action may be taken or such right may be exercised on the
next succeeding day not a Saturday, Sunday or legal holiday.

 

    	 - 2 -

    	 

    

 

8.
Adjustments. The Per Share Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment
from time to time as set forth in this Section 8.

 

(a)
Reclassification, etc. If the Company, at any time while this Warrant, or any portion hereof, remains outstanding and unexpired,
shall change by reclassification of securities or otherwise any of the securities as to which purchase rights under this Warrant exist
into the same or a different number of securities of any other kind, this Warrant shall thereafter represent the right to acquire such
number and kind of securities as would have been issuable as the result of such change with respect to the securities that were subject
to the purchase rights under this Warrant immediately prior to such reclassification or other change and the Exercise Price therefor
shall be appropriately adjusted, all subject to further adjustment as provided in this Section 8.

 

(b)
Subdivision or Combination of Shares of Common Stock. In the event that the Company shall at any time subdivide the outstanding
securities as to which purchase rights under this Warrant exist, or shall issue a stock dividend on the securities as to which purchase
rights under this Warrant exist, the number of securities as to which purchase rights under this Warrant exist immediately prior to such
subdivision or to the issuance of such stock dividend shall be proportionately increased, and the Exercise Price shall be proportionately
decreased, and in the event that the Company shall at any time combine the outstanding securities as to which purchase rights under this
Warrant exist, the number of securities as to which purchase rights under this Warrant exist immediately prior to such combination shall
be proportionately decreased, and the Exercise Price shall be proportionately increased, in each case effective as of the effective time
of such subdivision, stock dividend or combination, as the case may be.

 

(c)
Cash Distributions. No adjustment will be made to the Exercise Price or the number of securities as to which purchase rights under
this Warrant exist on account of cash dividends or interest on the securities as to which purchase rights under this Warrant exist.

 

9.
Miscellaneous.

 

(a)
Waiver and Amendment. Any provision of this Warrant may be amended, waived or modified upon the written consent of the Company
and the Holder.

 

(b)
Loss, Theft, Destruction or Mutilation of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement
reasonably satisfactory in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant,
the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount.

 

(c)
Notices. Any notice, request or other communication required or permitted hereunder shall be given in accordance with the Subscription
Agreement.

 

(d)
Successors and Assigns. This Warrant may be assigned or transferred by the Holder only with the prior written approval of the
Company. Subject to the preceding sentence, the rights and obligations of the Company and the Holder shall be binding upon and benefit
the successors, assigns, heirs, administrators and transferees of the parties.

 

(e)
Governing Law. This Warrant shall be governed by and construed in accordance with the internal laws of the State of Delaware without
giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would
cause the application of laws of any jurisdiction other than those of the State of Delaware.

 

[signature
page follows]

 

    	 - 3 -

    	 

    

 

IN
WITNESS WHEREOF, the Company and Holder have caused this Warrant to be executed by its officers thereunto duly authorized.

 

 

	[HOLDER]	 	BIOAFFINITY
    TECHNOLOGIES, INC.
	 	 	 	 	 
	By:	               	 	By:	 
	Name:	 	 	 	Maria
    Zannes
	Title:	 	 	 	Chief
    Executive Officer

 

    	 - 4 -

    	 

    

 

NOTICE
OF EXERCISE

 

	TO:	bioAffinity
    Technologies, Inc.

 

The
undersigned hereby elects to purchase ______________ shares (the “Shares”) of the Common Stock of BioAffinity Technologies,
Inc., pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price in full.

 

1.
Please issue a certificate or certificates representing the Shares in the name of the undersigned or in such other name as is specified
below:

 

	 	 	 	 
	 	(Print Name)	 
	 	 	 	 
	 	Address:  	 	 
	 	 	 	 
	 	 	 	 

 

2.
The undersigned represents that the Shares are being acquired for the account of the undersigned for investment only and not with a view
to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling
such Shares.

 

	 	 	 
	(Date)	 	(Signature)
	 	 	 
	 	 	 
	 	 	(Print
    Name)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]